Automate Your Wheel Strategy on ABBV
With Tiblio's Option Bot, you can configure your own wheel strategy including ABBV - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ABBV
- Rev/Share 33.6591
- Book/Share -1.4667
- PB -152.062
- Debt/Equity -26.0193
- CurrentRatio 0.7245
- ROIC 0.187
- MktCap 400663488345.0
- FreeCF/Share 11.6078
- PFCF 19.479
- PE 167.8145
- Debt/Assets 0.5134
- DivYield 0.0289
- ROE 4.9875
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | ABBV | HSBC Securities | Hold | Buy | -- | $265 | Dec. 10, 2025 |
| Initiation | ABBV | Scotiabank | -- | Sector Outperform | -- | $280 | Nov. 13, 2025 |
| Downgrade | ABBV | DZ Bank | Buy | Hold | -- | $237 | Nov. 4, 2025 |
| Downgrade | ABBV | Erste Group | Buy | Hold | -- | -- | Oct. 14, 2025 |
| Downgrade | ABBV | HSBC Securities | Buy | Hold | -- | -- | Oct. 1, 2025 |
| Upgrade | ABBV | Berenberg | Hold | Buy | -- | $270 | Sept. 17, 2025 |
| Resumed | ABBV | Piper Sandler | -- | Overweight | -- | $231 | Aug. 12, 2025 |
| Upgrade | ABBV | Daiwa Securities | Neutral | Outperform | -- | $214 | Aug. 7, 2025 |
| Downgrade | ABBV | Citigroup | Buy | Neutral | -- | $205 | May 14, 2025 |
| Initiation | ABBV | Cantor Fitzgerald | -- | Overweight | -- | $210 | April 22, 2025 |
News
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
Published: December 22, 2025 by: The Motley Fool
Sentiment: Positive
AbbVie is a Dividend King that successfully navigated a challenging patent cliff. Coca-Cola is a household name that has survived and thrived for 139 years.
Read More
Trump to announce new drug-pricing deals later today
Published: December 19, 2025 by: Market Watch
Sentiment: Positive
The White House is getting ready to announce more deals with drugmakers aimed at lowering drug prices.
Read More
Final Trades: Abbvie Inc, Microsoft, Netflix and Twilio Inc
Published: December 17, 2025 by: CNBC Television
Sentiment: Neutral
Market movers: The Investment Committee's top stocks to watch right now.
Read More
Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?
Published: December 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Read More
How AbbVie's Pipeline Is Lining Up Key Product Launches
Published: December 16, 2025 by: Zacks Investment Research
Sentiment: Neutral
ABBV is lining up multiple late-stage launches, from Rinvoq label expansions to Parkinson???s and oncology assets nearing FDA decisions.
Read More
This Dividend Pharma Giant Yielding 2.9% Just Got a Big Vote of Confidence
Published: December 10, 2025 by: 24/7 Wall Street
Sentiment: Positive
Healthcare stocks have lagged the broader market for the past three years, weighed down by post-COVID earnings volatility, policy uncertainties around drug pricing, and a surge in tech-driven gains from the AI boom.
Read More
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
Published: December 03, 2025 by: Zacks Investment Research
Sentiment: Positive
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
AbbVie and Pfizer: A Closer Look at Two Pharma Heavyweights
Published: November 26, 2025 by: Zacks Investment Research
Sentiment: Positive
ABBV's surging immunology sales and smoother LOE path stand out as both drugmakers face a pivotal 2026.
Read More
AbbVie and adMare BioInnovations Foster Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award in Quebec
Published: November 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
MONTREAL, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Today, AbbVie (NYSE: ABBV), jointly with the adMare BioInnovations, announced the launch of the AbbVie Biotech Innovators Award, a prize to help foster innovation and support growth in Quebec's life sciences sector.
Read More
2 Dividend Stocks to Hold Through Any Market Cycle
Published: November 19, 2025 by: 24/7 Wall Street
Sentiment: Neutral
Trying to build a portfolio that can survive recessions, inflation, and market volatility is one of the biggest challenges any investor can face.
Read More
AbbVie Stock Rebounds After Q3 Dip: Time to Buy, Hold or Sell?
Published: November 19, 2025 by: Zacks Investment Research
Sentiment: Positive
ABBV rebounds after its Q3 dip as strong immunology and neuroscience growth offset Humira erosion and aesthetics weakness.
Read More
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
Published: November 19, 2025 by: Zacks Investment Research
Sentiment: Positive
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma
Published: November 18, 2025 by: PRNewsWire
Sentiment: Neutral
- EPKINLY plus rituximab and lenalidomide (EPKINLY + R2) is now the first and only bispecific antibody combination therapy available for patients with relapsed or refractory follicular lymphoma after at least one line of systemic therapy - In the Phase 3 EPCORE® FL-1 trial, EPKINLY + R2 demonstrated significantly superior progression-free survival and overall response rates compared to standard of care R2 with approximately 3 out of 4 patients achieving a complete response - Approval marks third indication for EPKINLY and first-ever FDA approval for a bispecific combination therapy in lymphoma NORTH CHICAGO, Ill. , Nov. 18, 2025 /PRNewswire/ -- …
Read More
Here's How Neuroscience Drugs Aided AbbVie's Top-line Growth in Q3
Published: November 18, 2025 by: Zacks Investment Research
Sentiment: Positive
ABBV's neuroscience drugs drive strong Q3 momentum, with rising Botox Therapeutic sales, migraine therapies and new PD treatments fueling growth.
Read More
It's Best Time In 10 Years To Lock In Income: Our Picks
Published: November 18, 2025 by: Seeking Alpha
Sentiment: Positive
Investors can now access 4–7% from top-quality REITs, 3.5%+ from dividend ETFs, and 6%+ from midstream infrastructure — without taking on excessive risk. While the S&P 500 is up ~110% since 2020, 70–80% of returns come from the Mag7, leaving broad-market returns near inflation levels. US inflation sits at 3%, and Western Europe reports 3.5–4%, emphasizing the need for income-producing assets to preserve purchasing power for retirees.
Read More
Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman
Published: November 14, 2025 by: CNBC Television
Sentiment: Positive
Evan Seigerman, BMO Capital Markets head of health care research, joins 'Power Lunch' to discuss what's behind the recent move in health care stocks, the state of play with GLP-1s and much more.
Read More
How Much Did Skyrizi and Rinvoq Drive AbbVie's Q3 Performance?
Published: November 12, 2025 by: Zacks Investment Research
Sentiment: Positive
ABBV's growth engine keeps humming as Skyrizi and Rinvoq together now power more than 40% of total revenues and drive new market share gains.
Read More
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Read More
AbbVie Inc. (ABBV) Q3 2025 Earnings Call Transcript
Published: October 31, 2025 by: Seeking Alpha
Sentiment: Neutral
AbbVie Inc. ( ABBV ) Q3 2025 Earnings Call October 31, 2025 9:00 AM EDT Company Participants Elizabeth Shea - Senior Vice President of Investor Relations Robert Michael - CEO & Chairman of the Board Jeffrey Stewart - Executive VP & Chief Commercial Officer Roopal Thakkar - Executive VP of Research and Development & Chief Scientific Officer Scott Reents - Executive VP & CFO Conference Call Participants Terence Flynn - Morgan Stanley, Research Division Christopher Schott - JPMorgan Chase & Co, Research Division Vamil Divan - Guggenheim Securities, LLC, Research Division Matthew Phipps - William Blair & Company L.L.C., Research …
Read More
AbbVie Q3 Earnings & Sales Beat, 2025 EPS Outlook Raised
Published: October 31, 2025 by: Zacks Investment Research
Sentiment: Positive
ABBV tops Q3 earnings and revenue estimates, driven by Rinvoq and Skyrizi gains, and lifts its 2025 EPS outlook.
Read More
Demographic Megatrend: Stocks Poised to Benefit From Global Aging
Published: October 31, 2025 by: Zacks Investment Research
Sentiment: Positive
Global aging is reshaping healthcare demand. Discover how AbbVie, Amgen, Boston Scientific and Edwards are positioned to gain from this powerful megatrend.
Read More
AbbVie (ABBV) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Published: October 31, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
AbbVie: Why Q3 Confirms Its Immunology Dominance
Published: October 31, 2025 by: Seeking Alpha
Sentiment: Positive
AbbVie Inc., 2 hours ago, published monstrous results for Q3, once again strengthening my confidence that it is a "powerhouse" in the autoimmune disease drugs market. Net revenues from AbbVie's immunology portfolio totaled $7.89 billion this quarter, compared to $7.05 billion in Q3 2024. Sales of Elahere, an ADC used to treat ovarian cancer, reached $170 million in Q3 2025, up 22.3% year-on-year and 6.9% quarter-on-quarter.
Read More
AbbVie (ABBV) Q3 Earnings and Revenues Surpass Estimates
Published: October 31, 2025 by: Zacks Investment Research
Sentiment: Positive
AbbVie (ABBV) came out with quarterly earnings of $1.86 per share, beating the Zacks Consensus Estimate of $1.77 per share. This compares to earnings of $3 per share a year ago.
Read More
5 Dividend ETFs That Could Pay You for Life
Published: October 31, 2025 by: 24/7 Wall Street
Sentiment: Positive
Whether you're just beginning to invest or sailing into retirement, you can benefit from a lifetime stream of passive income.
Read More
AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (RINVOQ®) in Adults and Adolescents with Vitiligo
Published: October 29, 2025 by: PRNewsWire
Sentiment: Neutral
In two replicate Phase 3 studies, upadacitinib (RINVOQ ® ) achieved the co-primary endpoints of 50% reduction in Total Vitiligo Area Scoring Index (T-VASI 50) from baseline and 75% reduction in Facial Vitiligo Area Scoring Index (F-VASI 75) from baseline at week 481 Both studies met key ranked secondary endpoints1 NORTH CHICAGO, Ill. , Oct. 29, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from two replicate Phase 3 studies evaluating the safety and efficacy of upadacitinib (RINVOQ®;15 mg, once daily in adult and adolescent patients living with non-segmental vitiligo (NSV).1 NSV, the most common form of …
Read More
AbbVie: Deep Discount Before Earnings
Published: October 28, 2025 by: Seeking Alpha
Sentiment: Positive
AbbVie Inc. is reiterated as a Strong Buy ahead of Q3 earnings, with revenue growth expected to outpace the sector median. ABBV consistently delivers double beats, maintains robust FCF margins, and is investing aggressively in R&D for future growth. The DDM model suggests ABBV is significantly undervalued, with a fair value estimate indicating 27% upside potential over the next year.
Read More
Healthy Returns: What to expect from Eli Lilly, Merck, Gilead and AbbVie third-quarter earnings
Published: October 28, 2025 by: CNBC
Sentiment: Positive
Eli Lilly, Merck, Gilead, Bristol Myers Squibb and AbbVie, among other pharmaceutical companies, are slated to report third-quarter earnings this week.
Read More
Should You Buy AbbVie Stock Ahead of Q3 Earnings Report?
Published: October 28, 2025 by: Zacks Investment Research
Sentiment: Negative
ABBV's Q3 results are likely to hinge on Skyrizi and Rinvoq growth, as Humira erosion and hefty IPR&D charges are expected to pressure near-term earnings.
Read More
What's in Store for These 5 Pharma Bigwigs This Earnings Season?
Published: October 27, 2025 by: Zacks Investment Research
Sentiment: Neutral
As earnings season accelerates, pharma heavyweights LLY, MRK, ABBV, BMY and GILD prepare to reveal their Q3 results amid a strong sector start.
Read More
About AbbVie Inc. (ABBV)
- IPO Date 2013-01-02
- Website https://www.abbvie.com
- Industry Drug Manufacturers - General
- CEO Robert A. Michael
- Employees 55000